FR3035105A1 - Derives utiles dans le traitement de l'atrophie musculaire - Google Patents

Derives utiles dans le traitement de l'atrophie musculaire Download PDF

Info

Publication number
FR3035105A1
FR3035105A1 FR1553410A FR1553410A FR3035105A1 FR 3035105 A1 FR3035105 A1 FR 3035105A1 FR 1553410 A FR1553410 A FR 1553410A FR 1553410 A FR1553410 A FR 1553410A FR 3035105 A1 FR3035105 A1 FR 3035105A1
Authority
FR
France
Prior art keywords
group
advantageously
dichlorophenyl
alkyl group
ethoxyimino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
FR1553410A
Other languages
English (en)
French (fr)
Inventor
Sophie N Raynal
Micheline R Kergoat
Valerie Autier
Christine G Charon
Jean-Denis Durand
Franck F Lepifre
Annick M Audet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabrain Research
Original Assignee
Metabrain Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabrain Research filed Critical Metabrain Research
Priority to FR1553410A priority Critical patent/FR3035105A1/fr
Priority to ES16729310T priority patent/ES2741012T3/es
Priority to EP16729310.9A priority patent/EP3283064B1/fr
Priority to PCT/FR2016/050864 priority patent/WO2016166480A1/fr
Priority to CA2988625A priority patent/CA2988625A1/en
Priority to KR1020177033178A priority patent/KR20170137201A/ko
Priority to RU2017139915A priority patent/RU2715553C2/ru
Priority to PL16729310T priority patent/PL3283064T3/pl
Priority to DK16729310.9T priority patent/DK3283064T3/da
Priority to PT16729310T priority patent/PT3283064T/pt
Priority to JP2017554365A priority patent/JP6669774B2/ja
Priority to CN201680034525.4A priority patent/CN107735082B/zh
Priority to US15/566,955 priority patent/US10350184B2/en
Publication of FR3035105A1 publication Critical patent/FR3035105A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
FR1553410A 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire Ceased FR3035105A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1553410A FR3035105A1 (fr) 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire
ES16729310T ES2741012T3 (es) 2015-04-16 2016-04-14 Derivados utilizados en el tratamiento de atrofia muscular
EP16729310.9A EP3283064B1 (fr) 2015-04-16 2016-04-14 Dérives utiles dans le traitement de l'atrophie musculaire
PCT/FR2016/050864 WO2016166480A1 (fr) 2015-04-16 2016-04-14 Dérives utiles dans le traitement de l'atrophie musculaire
CA2988625A CA2988625A1 (en) 2015-04-16 2016-04-14 (3,4-dichlorophenyl)-4- alkylimino compounds useful in the treatment of muscle atrophy and sarcopenia
KR1020177033178A KR20170137201A (ko) 2015-04-16 2016-04-14 근육 위축 치료에 사용되는 유도체
RU2017139915A RU2715553C2 (ru) 2015-04-16 2016-04-14 Производные, применяемые для лечения мышечной атрофии
PL16729310T PL3283064T3 (pl) 2015-04-16 2016-04-14 Pochodne do zastosowania w atrofii mięśni
DK16729310.9T DK3283064T3 (da) 2015-04-16 2016-04-14 Derivater til anvendelse i behandling af muskelatrofi
PT16729310T PT3283064T (pt) 2015-04-16 2016-04-14 Derivados úteis para o tratamento da atrofia muscular
JP2017554365A JP6669774B2 (ja) 2015-04-16 2016-04-14 筋萎縮の治療に有用な誘導体
CN201680034525.4A CN107735082B (zh) 2015-04-16 2016-04-14 用于治疗肌肉萎缩的衍生物
US15/566,955 US10350184B2 (en) 2015-04-16 2016-04-14 Derivatives used in the treatment of muscle atrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1553410A FR3035105A1 (fr) 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire

Publications (1)

Publication Number Publication Date
FR3035105A1 true FR3035105A1 (fr) 2016-10-21

Family

ID=53758355

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1553410A Ceased FR3035105A1 (fr) 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire

Country Status (13)

Country Link
US (1) US10350184B2 (enExample)
EP (1) EP3283064B1 (enExample)
JP (1) JP6669774B2 (enExample)
KR (1) KR20170137201A (enExample)
CN (1) CN107735082B (enExample)
CA (1) CA2988625A1 (enExample)
DK (1) DK3283064T3 (enExample)
ES (1) ES2741012T3 (enExample)
FR (1) FR3035105A1 (enExample)
PL (1) PL3283064T3 (enExample)
PT (1) PT3283064T (enExample)
RU (1) RU2715553C2 (enExample)
WO (1) WO2016166480A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
CN111253246B (zh) * 2020-03-16 2023-03-17 中国医学科学院基础医学研究所 酰基酸类衍生物及其制备方法和医药用途
CN114533731B (zh) * 2022-02-25 2024-06-04 上海大学 一种氨基吡啶衍生物在制备肌肉萎缩抑制剂中的应用
CN117205215B (zh) * 2023-11-08 2024-01-26 广州喜鹊医药有限公司 川芎嗪硝酮衍生物在制备预防或治疗肌少症药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204406A1 (en) * 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US20020161050A1 (en) * 1999-07-12 2002-10-31 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401912T4 (tr) * 2000-03-20 2004-09-21 N-Gene Research Laboratories Inc. Propenkarboksilik asit amidoksim türevleri, bu türevlerin hazırlanması için işlem ve bu türevleri ihtiva eden farmasötik bileşimler
DK2774925T3 (en) * 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
WO2017044551A1 (en) * 2015-09-11 2017-03-16 Mitobridge, Inc. Ppar-alpha agonists for treating mitochondrial diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204406A1 (en) * 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US20020161050A1 (en) * 1999-07-12 2002-10-31 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Also Published As

Publication number Publication date
EP3283064B1 (fr) 2019-05-08
CA2988625A1 (en) 2016-10-20
RU2715553C2 (ru) 2020-03-02
RU2017139915A (ru) 2019-05-17
ES2741012T3 (es) 2020-02-07
CN107735082B (zh) 2021-07-27
JP6669774B2 (ja) 2020-03-25
CN107735082A (zh) 2018-02-23
KR20170137201A (ko) 2017-12-12
PT3283064T (pt) 2019-08-21
US20180303780A1 (en) 2018-10-25
EP3283064A1 (fr) 2018-02-21
JP2018513162A (ja) 2018-05-24
WO2016166480A1 (fr) 2016-10-20
DK3283064T3 (da) 2019-08-12
US10350184B2 (en) 2019-07-16
PL3283064T3 (pl) 2019-12-31
RU2017139915A3 (enExample) 2019-06-06

Similar Documents

Publication Publication Date Title
EP3283064B1 (fr) Dérives utiles dans le traitement de l&#39;atrophie musculaire
CN101674730B (zh) 用于治疗代谢疾病的组合物和方法
CN103037692B (zh) 用于抑制肌萎缩的方法
EP3145942B1 (fr) Composés chimiques et leur utilisation pour l&#39;amélioration de la qualité musculaire
EP3615035B1 (fr) Utilisation de 20-hydroxyecdysone et ses dérivés dans le traitement des myopathies
EP2542239B1 (fr) Utilisation d&#39;isoquinolones pour la preparation de medicaments, nouvelles isoquinolones et leur procede de synthese
JP2023116525A (ja) 網膜細胞への線維芽細胞の再プログラミング方法
EP3506901B1 (fr) Utilisation de l&#39;acide kynurénique dans le traitement de l&#39;atrophie musculaire
CA2879054C (fr) Derives d&#39;imidazopyridine utiles dans le traitement du diabete
CA2817388C (fr) Derives de quinolinone
WO2000030643A1 (fr) Nouvelle application therapeutique de la nicergoline
EP3634957B1 (fr) Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composés dans le traitement de maladies impliquant le systeme nerveux central
FR2763847A1 (fr) Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
EP3353165B1 (fr) 1,4-di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one et ses derives
FR3069434A1 (fr) Acide anthranilique dans le traitement de l&#39;atrophie musculaire
WO1999040911A1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d&#39;alzheimer
RU2806346C2 (ru) Использование метаболитов триптофана для лечения мышечной атрофии
HK1238578A1 (en) Methods of inhibiting muscle atrophy
WO2009044006A2 (fr) L&#39;acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20161021

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

RX Complete rejection

Effective date: 20210812